is tirzepatide safe for fatty liver issue Benefits of Injections Tirzepatide and Fatty Liver Disease:

BPC-157 has an excellent safety record with virtually no serious side effects

The Endocrine Society's 2015 obesity pharmacotherapy guidelines recommend that "dose escalation be delayed for patients experiencing intolerable adverse events." This applies directly to GLP-1 agents and gives prescribers explicit guideline backing to slow the titration schedule when needed [12]

Thyroid function should be monitored at baseline, 812 weeks after starting treatment, and during significant weight changes to ensure optimal dosing

The dose can be increased up to a maximum of 14mg

1 Oral glucose stimulates the release of the endogenous incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP)

Methods We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024